Log in

Regenxbio Stock Price, News & Analysis (NASDAQ:RGNX)

$37.75
-1.28 (-3.28 %)
(As of 10/21/2019 06:08 AM ET)
Today's Range
$36.87
Now: $37.75
$39.00
50-Day Range
$31.84
MA: $36.45
$39.90
52-Week Range
$30.38
Now: $37.75
$73.81
Volume269,984 shs
Average Volume585,040 shs
Market Capitalization$1.39 billion
P/E Ratio15.86
Dividend YieldN/A
Beta0.82
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$218.51 million
Cash Flow$2.48 per share
Book Value$14.20 per share

Profitability

Net Income$99.94 million

Miscellaneous

Employees192
Market Cap$1.39 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.


Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) announced its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.46. The biotechnology company earned $7.88 million during the quarter, compared to analyst estimates of $5.45 million. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The firm's revenue for the quarter was down 80.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.30 earnings per share. View Regenxbio's Earnings History.

When is Regenxbio's next earnings date?

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Regenxbio.

What price target have analysts set for RGNX?

8 analysts have issued 1-year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's share price to reach $79.13 in the next year. This suggests a possible upside of 109.6% from the stock's current price. View Analyst Price Targets for Regenxbio.

What is the consensus analysts' recommendation for Regenxbio?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

What are Wall Street analysts saying about Regenxbio stock?

Here are some recent quotes from research analysts about Regenxbio stock:
  • 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (10/16/2019)
  • 2. Chardan Capital analysts commented, "We note Sarepta Therapeutics (unrated) may be relevant for that theme. The IP discussion began by REGENXBIO discussing Zolgensma and the agreement with Avexis, a Novartis (unrated) company, where REGENXBIO will receive tiered royalties of 6%, 8%, and 10% on Zolgensma sales of $600 mm, respectively, as well as a milestone payment of $80 mm once Zolgensma reaches $1 bn in aggregate sales." (6/18/2019)

Has Regenxbio been receiving favorable news coverage?

Headlines about RGNX stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regenxbio earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Regenxbio.

Are investors shorting Regenxbio?

Regenxbio saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,170,000 shares, an increase of 15.5% from the August 30th total of 3,610,000 shares. Based on an average daily volume of 564,400 shares, the short-interest ratio is currently 7.4 days. Approximately 12.6% of the company's shares are sold short. View Regenxbio's Current Options Chain.

Who are some of Regenxbio's key competitors?

What other stocks do shareholders of Regenxbio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), Micron Technology (MU), Exelixis (EXEL), Amarin (AMRN), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), Alibaba Group (BABA), Bausch Health Companies (BHC) and Square (SQ).

Who are Regenxbio's key executives?

Regenxbio's management team includes the folowing people:
  • Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
  • Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
  • Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
  • Dr. Olivier Danos, Chief Scientific Officer (Age 61)
  • Dr. Stephen Yoo, Consultant (Age 41)

Who are Regenxbio's major shareholders?

Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%) and NEXT Financial Group Inc (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

Which major investors are buying Regenxbio stock?

RGNX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and NEXT Financial Group Inc. View Insider Buying and Selling for Regenxbio.

How do I buy shares of Regenxbio?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regenxbio's stock price today?

One share of RGNX stock can currently be purchased for approximately $37.75.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $1.39 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

What is Regenxbio's official website?

The official website for Regenxbio is http://www.regenxbio.com/.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]


MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  594
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel